Stay updated on QBW251 Dose-range Efficacy & Safety in COPD Clinical Trial

Sign up to get notified when there's something new on the QBW251 Dose-range Efficacy & Safety in COPD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the QBW251 Dose-range Efficacy & Safety in COPD Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a modification in the dose range being evaluated for QBW251 in COPD patients with chronic bronchitis and a history of exacerbations, compared to placebo, when added to a triple inhaled therapy of LABA, LAMA, and ICS.
    Difference
    0.1%
    Check dated 2024-06-06T14:34:43.000Z thumbnail image
  7. Check
    22 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying that male and female COPD patients aged 40 years and older, who are current or ex-smokers with a history of at least 10 pack years, and have been treated with a triple combination of LABA/LAMA/ICS for the last 3 months, are eligible. Previously, no information was provided under Participation Criteria.
    Difference
    12%
    Check dated 2024-05-22T21:36:30.000Z thumbnail image
  8. Check
    44 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:40:23.000Z thumbnail image

Stay in the know with updates to QBW251 Dose-range Efficacy & Safety in COPD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the QBW251 Dose-range Efficacy & Safety in COPD Clinical Trial page.